Navigation Links
Owing to Generic Erosion of Key Agents, the Colorectal Cancer Drug Market Will Remain Relatively Flat Through 2019
Date:9/22/2010

BURLINGTON, Mass., Sept. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, owing to generic erosion of key agents, the colorectal cancer drug market will remain relatively flat over the next decade, increasing from more than $6.4 billion in 2009 to just under $6.7 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Colorectal Cancer reveal that the market leader -- Genentech/Roche/Chugai's Avastin -- will be minimally challenged in the colorectal cancer drug market over the next decade. Despite the emergence of biosimilar versions of Avastin, which is expected to begin in 2018, and increasing first-line use of other targeted agents, Avastin sales will decline only slightly from just over $2 billion in 2009 to $1.86 billion in 2019. Additionally, the entry of two new vascular endothelial growth factor (VEGF)-targeted agents into the market, Regeneron/Sanofi-Aventis's aflibercept (VEGF Trap) and ImClone Systems/Eli Lilly's ramucirumab, will fail to make a significant impact, together garnering only 4.9% of major market sales.

The Pharmacor 2010 findings also reveal that Bristol-Myers Squibb/ImClone Systems/Merck Serono's Erbitux dominates the epidermal growth factor receptor (EGFR) inhibitors class, mainly because it was first drug in its class to launch for the indication, it can be used in combination with chemotherapy and has been approved in Europe and Japan for use in the lucrative first-line setting.

"Through 2019, Erbitux's market share will grow incrementally, even in the face of biogeneric erosion and the use of additional anti-EGFR treatments in the first- and second-line settings," said Decision Resources Analyst Regina Jammen. "Erbitux's first-to-market position has helped establish it as the market-leading anti-EGFR therapy."

The findings also reveal that, although a variety of suitable treatments for the indication are available, new therapies are required that will meet the needs of subsets of colorectal cancer patients. Several treatments that are expected to launch by 2019 will meet some of the needs of heavily pretreated patients with KRAS (Kirsten rat sarcoma viral oncogene homologue) mutations, patients with liver metastases and high-risk stage II patients. These late-stage therapies include AEterna Zentaris/Keryx Biopharmaceuticals' perifosine (KRX-0401), Light Sciences Oncology/Nippon Petrochemicals/Meiji Seika Kaisha's Aptocine/Laserphyrin (talaporfin) and the OncoVax vaccine, Vaccinogen.

"However, we forecast that none of these late-stage therapies will achieve blockbuster sales for colorectal cancer," Ms. Jammen said.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
2. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
3. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
4. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
5. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
6. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
7. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
10. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
11. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/22/2017)... ROCKVILLE, Md. , Sept. 22, 2017  As ... by Republican Senators Bill Cassidy (R-LA) and ... Kalorama Information notes that the medical device industry is ... the medical device tax, the 2.3% excise tax on ... Act.  But they also want covered patients, increased visits ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
Breaking Medicine News(10 mins):